• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Does increased expression of glucocorticoid receptor support application of antagonists to this receptor for the treatment of castration resistant prostate cancer?

作者信息

Hirayama Yukiyoshi, Sadar Marianne D

机构信息

Genome Sciences Centre, BC Cancer, Vancouver, Canada.

出版信息

AME Med J. 2018 Jun;3. doi: 10.21037/amj.2018.06.02. Epub 2018 Jun 13.

DOI:10.21037/amj.2018.06.02
PMID:30198014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6124673/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54c5/6124673/1aeb344c874c/nihms-983728-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54c5/6124673/1aeb344c874c/nihms-983728-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54c5/6124673/1aeb344c874c/nihms-983728-f0001.jpg

相似文献

1
Does increased expression of glucocorticoid receptor support application of antagonists to this receptor for the treatment of castration resistant prostate cancer?糖皮质激素受体表达增加是否支持应用该受体拮抗剂治疗去势抵抗性前列腺癌？
AME Med J. 2018 Jun;3. doi: 10.21037/amj.2018.06.02. Epub 2018 Jun 13.
2
The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside.糖皮质激素受体在前列腺癌进展中的作用：从实验台到病床边
Int Urol Nephrol. 2017 Mar;49(3):369-380. doi: 10.1007/s11255-016-1476-8. Epub 2016 Dec 16.
3
The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.糖皮质激素受体的表达受前列腺肿瘤中雄激素受体信号的正向调节。
Int J Cancer. 2015 Feb 15;136(4):E27-38. doi: 10.1002/ijc.29147. Epub 2014 Aug 27.
4
[ASC-J9 for castration-resistant prostate cancer].[用于去势抵抗性前列腺癌的ASC-J9]
Nihon Rinsho. 2014 Dec;72(12):2126-9.
5
PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.PXD101 增强了激素治疗效果，并在前列腺癌的临床前模型中调节雄激素受体、HSP90 和 CRM1，防止了去势抵抗表型的发生。
Endocr Relat Cancer. 2013 May 21;20(3):321-37. doi: 10.1530/ERC-12-0240. Print 2013 Jun.
6
Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.患者来源的激素敏感型前列腺癌异种移植模型揭示生长因子受体结合蛋白 10 作为雄激素受体抑制基因，驱动去势抵抗性前列腺癌的发展。
Eur Urol. 2018 Jun;73(6):949-960. doi: 10.1016/j.eururo.2018.02.019. Epub 2018 Mar 12.
7
Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.利用新型异种移植模型鉴定 EP4 作为治疗去势抵抗性前列腺癌的潜在靶点。
Cancer Res. 2010 Feb 15;70(4):1606-15. doi: 10.1158/0008-5472.CAN-09-2984. Epub 2010 Feb 9.
8
Apalutamide for the treatment of patients with castration-resistant prostate cancer.阿帕鲁胺用于治疗去势抵抗性前列腺癌患者。
Drugs Today (Barc). 2018 Oct;54(10):585-590. doi: 10.1358/dot.2018.54.10.2885880.
9
Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.去势抵抗性前列腺癌中雄激素受体靶向治疗：从实验室到临床
Int J Urol. 2016 Aug;23(8):654-65. doi: 10.1111/iju.13137. Epub 2016 Jun 14.
10
RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.RGS2对去势抵抗性前列腺癌中去势抵抗的发展及癌症特异性生存具有预后价值。
Prostate. 2020 Aug;80(11):799-810. doi: 10.1002/pros.23994. Epub 2020 May 25.

引用本文的文献

1
Nuclear receptors in health and disease: signaling pathways, biological functions and pharmaceutical interventions.健康与疾病中的核受体：信号通路、生物学功能及药物干预
Signal Transduct Target Ther. 2025 Jul 28;10(1):228. doi: 10.1038/s41392-025-02270-3.
2
A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers therapeutic resistance in prostate cancer.由TBX2驱动的从雄激素受体到糖皮质激素受体的信号转导开关赋予前列腺癌治疗抗性。
Oncogene. 2025 Apr;44(13):877-892. doi: 10.1038/s41388-024-03252-5. Epub 2024 Dec 20.
3
Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo.

本文引用的文献

1
Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy.雄激素-糖皮质激素相互作用在新型前列腺癌治疗时代。
Nat Rev Urol. 2016 Jan;13(1):47-60. doi: 10.1038/nrurol.2015.254. Epub 2015 Dec 8.
2
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.前列腺癌中对雄激素受体抑制剂耐药的新机制
Nat Rev Cancer. 2015 Dec;15(12):701-11. doi: 10.1038/nrc4016. Epub 2015 Nov 13.
3
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.阿比特龙转化为D4A可驱动前列腺癌的抗肿瘤活性。
转移性去势抵抗性前列腺癌中的耐药性：现状更新
Cancer Drug Resist. 2022 Jun 22;5(3):667-690. doi: 10.20517/cdr.2022.15. eCollection 2022.
4
Advances in the Current Understanding of the Mechanisms Governing the Acquisition of Castration-Resistant Prostate Cancer.去势抵抗性前列腺癌获得机制的当前理解进展
Cancers (Basel). 2022 Jul 31;14(15):3744. doi: 10.3390/cancers14153744.
5
Development of a High-Throughput Screening Assay for Small-Molecule Inhibitors of Androgen Receptor Splice Variants.高通量筛选雄激素受体剪接变体小分子抑制剂的方法研究。
Assay Drug Dev Technol. 2022 Apr;20(3):111-124. doi: 10.1089/adt.2021.128. Epub 2022 Mar 23.
6
Cyproterone acetate acts as a disruptor of the aryl hydrocarbon receptor.醋酸环丙孕酮可作为芳烃受体的拮抗剂。
Sci Rep. 2021 Mar 9;11(1):5457. doi: 10.1038/s41598-021-84769-7.
7
Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?前列腺癌中抗雄激素耐药：是不可避免的、内在的还是诱导产生的？
Cancers (Basel). 2021 Jan 17;13(2):327. doi: 10.3390/cancers13020327.
8
Emerging role of glucocorticoid receptor in castration resistant prostate cancer: A potential therapeutic target.糖皮质激素受体在去势抵抗性前列腺癌中的新作用：一个潜在的治疗靶点。
J Cancer. 2020 Jan 1;11(3):696-701. doi: 10.7150/jca.32497. eCollection 2020.
Nature. 2015 Jul 16;523(7560):347-51. doi: 10.1038/nature14406. Epub 2015 Jun 1.
4
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.醋酸阿比特龙联合泼尼松对比安慰剂联合泼尼松治疗化疗初治转移性去势抵抗性前列腺癌患者（COU-AA-302）：一项随机、双盲、安慰剂对照的 3 期研究的最终总生存分析。
Lancet Oncol. 2015 Feb;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7. Epub 2015 Jan 16.
5
A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer.地塞米松与泼尼松龙治疗去势抵抗性前列腺癌的随机 2 期临床试验。
Eur Urol. 2015 Apr;67(4):673-9. doi: 10.1016/j.eururo.2014.10.004. Epub 2014 Oct 16.
6
The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.糖皮质激素受体的表达受前列腺肿瘤中雄激素受体信号的正向调节。
Int J Cancer. 2015 Feb 15;136(4):E27-38. doi: 10.1002/ijc.29147. Epub 2014 Aug 27.
7
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.糖皮质激素受体活性有助于前列腺癌对雄激素靶向治疗的抵抗。
Horm Cancer. 2014 Apr;5(2):72-89. doi: 10.1007/s12672-014-0173-2. Epub 2014 Mar 11.
8
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.糖皮质激素受体通过绕过雄激素受体阻断来赋予抗雄激素药物耐药性。
Cell. 2013 Dec 5;155(6):1309-22. doi: 10.1016/j.cell.2013.11.012.
9
A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.米非司酮（RU-486）用于去势抵抗性前列腺癌的II期研究及雄激素相关激素的关联评估。
BJU Int. 2008 May;101(9):1084-9. doi: 10.1111/j.1464-410X.2008.07509.x.
10
Cell- and gene-specific regulation of primary target genes by the androgen receptor.雄激素受体对初级靶基因的细胞和基因特异性调控。
Genes Dev. 2007 Aug 15;21(16):2005-17. doi: 10.1101/gad.1564207.